Lo Cascio V, Adami S, Galvanini G, Lazzaretto R, Ferrari M, Tartarotti D, Scuro L A
J Endocrinol Invest. 1984 Apr;7(2):85-8. doi: 10.1007/BF03348394.
Eleven patients with Paget's disease of bone, treated intermittently for 2-4 years with porcine calcitonin (pCT) and clinically resistant to pCT [no modifications of serum alkaline phosphatase (ALP) and urinary hydroxyproline ( uHOP ) during pCT administration] were treated with 0.5-0.25 mg/day of human calcitonin (hCT) for 3-6 months. Nine of our patients showed biochemical improvement during the first 2 months of treatment, with reduction in ALP and uHOP . In one patient with slightly increased ALP and uHOP , and in another one during the second treatment course, hCT treatment did not modify the biochemical indices of bone disease. However all patients, including those with biochemical resistance, experienced a remarkable diminution of bone pain, which had not been observed during previous pCT treatment courses. Therefore, hCT appears to be indicated for therapeutic use in patients who are resistant to foreign calcitonins.
11例骨Paget病患者，曾间断使用猪降钙素（pCT）治疗2 - 4年，且对pCT临床耐药（pCT给药期间血清碱性磷酸酶（ALP）和尿羟脯氨酸（uHOP）无变化），给予人降钙素（hCT）0.5 - 0.25mg/天治疗3 - 6个月。我们的9例患者在治疗的前2个月出现生化指标改善，ALP和uHOP降低。1例ALP和uHOP略有升高的患者，以及另1例在第二个疗程治疗期间的患者，hCT治疗未改变骨病的生化指标。然而，所有患者，包括那些生化耐药的患者，骨痛均显著减轻，这在之前的pCT治疗疗程中未观察到。因此，hCT似乎适用于对异体降钙素耐药的患者进行治疗。
